The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment (Q77482076)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

title

The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

G E Hogarty

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

R F Ulrich

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

Journal of Psychiatric Research

5 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

issue

3-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

243-250

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

Family treatment of adult schizophrenic patients: a psycho-educational approach

5 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Neuroleptic withdrawal in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Psychosocial treatment for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

DISCONTINUATION OR REDUCTION OF CHEMOTHERAPY IN CHRONIC SCHIZOPHRENICS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

A randomised controlled trial of prophylactic neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Family interventions for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two-year longitudinal study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled study on relapse and adjustment. Environmental-Personal Indicators in the Course of Schizo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Personal therapy: a disorder-relevant psychotherapy for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Temporal Effects of Drug and Placebo in Delaying Relapse in Schizophrenic Outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Considering neuroleptic maintenance and taper on a continuum. Need for individual rather than dogmatic approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Results of simultaneous abrupt withdrawal of ataraxics in 500 chronic psychotic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Recent developments in expressed emotion and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

A controlled trial of social intervention in the families of schizophrenic patients: two year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Vocational rehabilitation in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Treatment outcomes in schizophrenia: implications for practice, policy, and research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Optimal drug and behavior therapy for treatment-refractory schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

High Dose Trifluoperazine Therapy in Chronic Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Assertive community treatment and case management for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Psychological interventions for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2897%2900013-7

10.1016/S0022-3956(97)00013-7

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9793877%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference